Precision Immunotherapy Development & Advanced Antibody Engineering
Apheon Bioscience is a preclinical biotech developing first-in-class immunotherapies for high-burden diseases in women’s health. We leverage our ApheGenixID™ antigen discovery and immunotherapy development platform to accelerate development of high-value therapeutic assets for our proprietary portfolio and strategic partners. We also offer our platform capabilities as standalone services, including immunotherapy development, antibody engineering, and DNA cloning.
Precision DNA Cloning to Power Your Next Discovery
Your critical constructs shouldn’t be a bottleneck—or a compromise.
Internal cloning drains scientific talent, while traditional outsourcing often forces rigid, proprietary vector sets. Apheon Bioscience breaks this cycle. Our automated platform acts as a seamless extension of your lab, delivering custom plasmids with a level of speed, precision, and cost-efficiency that manual methods and “standard” providers cannot match.
The Apheon Advantage:
- Zero-Cost Vector Onboarding: Eliminate customization fees and transfer delays. We onboard your proprietary vectors at no cost, ensuring you get the constructs you want in the vector you need.
- BIOSECURE Act Compliance: All cloning and data handling are conducted exclusively in the U.S., securing your domestic supply chain and protecting eligibility for federal grants and contracts.
- Reallocate Scientific Capital: Relieve your team of the cloning burden. We deliver sequence-verified plasmids so your researchers can focus on high-value downstream innovation.
- Optimize Budgets & Timelines: Reduce overhead and eliminate troubleshooting delays by leveraging our high-throughput automated workflows and economies of scale.
Let’s talk about your next construct.
Pioneering Discovery & Specialized Research Services
We partner with leading institutions, biotechnology and pharmaceutical companies to translate breakthrough science into differentiated therapeutic assets.
Immunotherapy Development & Target Identification
Apheon Bioscience is advancing a focused portfolio of first-in-class immunotherapies targeting high-burden, underserved conditions in women’s health including Triple- Negative Breast Cancer (TNBC), Leiomyosarcoma, and Endometriosis. Beyond our internal pipeline, we offer our proprietary ApheGenixID™ platform as a standalone service for partners seeking to identify exclusive, tumor-associated antigens and accelerate the discovery of high-value clinical candidates.
Precision Recombinant Antibody Engineering
Accelerate your path to high-performance leads with our versatile antibody development suite. By integrating AI-driven design, high-diversity library screening, and hybridoma rescue, we provide a precise, scalable alternative to traditional discovery methods. Our platform supports multiple isotypes and species, engineered to meet the rigorous standards of early discovery and preclinical development for any therapeutic modality.
Driving Research Innovation Through Expertise and Collaboration
Our team integrates deep expertise in molecular biology, immunology, and translational research to develop a robust, partnership-ready technology stack. Our ApheGenixID™ platform is designed to accelerate the identification of tumor-associated antigens and recovery of high-affinity leads. By combining this proprietary discovery engine with a commitment to scientific rigor, we unlock first-in-class opportunities for pharmaceutical companies and R&D institutions looking to advance the next generation of immunotherapies.
Strategic Partnerships & Investment Opportunities
What we do
Our team integrates deep expertise in molecular biology, immunology, and translational research to develop a robust, partnership-ready technology stack. Our ApheGenixID™ platform is designed to accelerate the identification of tumor-associated antigens and recovery of high-affinity leads.
By combining this proprietary discovery engine with a commitment to scientific rigor, we unlock first-in-class opportunities for pharmaceutical companies and R&D institutions looking to advance the next generation of immunotherapies.
